ASX - By Stock
|
MSB |
Re:
MESO Nasdaq update
|
|
Cooper111
|
5.0K |
2.5M |
0 |
03/04/24 |
03/04/24 |
ASX - By Stock
|
5.0K
|
2.5M
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Grants Rare Pediatric Disease Designation for Revascor
|
|
Cooper111
|
380 |
126K |
13 |
24/01/24 |
24/01/24 |
ASX - By Stock
|
380
|
126K
|
13
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Trading Halt
|
|
Cooper111
|
1.3K |
544K |
6 |
14/08/23 |
14/08/23 |
ASX - By Stock
|
1.3K
|
544K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Why a trial?
|
|
Cooper111
|
107 |
34K |
8 |
13/08/23 |
13/08/23 |
ASX - By Stock
|
107
|
34K
|
8
|
|
ASX - By Stock
|
MSB |
Re:
Why a trial?
|
|
Cooper111
|
107 |
34K |
11 |
13/08/23 |
13/08/23 |
ASX - By Stock
|
107
|
34K
|
11
|
|
ASX - By Stock
|
MSB |
Re:
Why a trial?
|
|
Cooper111
|
107 |
34K |
13 |
11/08/23 |
11/08/23 |
ASX - By Stock
|
107
|
34K
|
13
|
|
ASX - By Stock
|
MSB |
Re:
Why a trial?
|
|
Cooper111
|
107 |
34K |
13 |
11/08/23 |
11/08/23 |
ASX - By Stock
|
107
|
34K
|
13
|
|
ASX - By Stock
|
MSB |
Re:
CEO Itescu needs to go
|
|
Cooper111
|
904 |
275K |
5 |
11/08/23 |
11/08/23 |
ASX - By Stock
|
904
|
275K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
CEO Itescu needs to go
|
|
Cooper111
|
904 |
275K |
4 |
10/08/23 |
10/08/23 |
ASX - By Stock
|
904
|
275K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
CEO Itescu needs to go
|
|
Cooper111
|
904 |
275K |
14 |
09/08/23 |
09/08/23 |
ASX - By Stock
|
904
|
275K
|
14
|
|
ASX - By Stock
|
MSB |
Re:
CEO Itescu needs to go
|
|
Cooper111
|
904 |
275K |
8 |
08/08/23 |
08/08/23 |
ASX - By Stock
|
904
|
275K
|
8
|
|
ASX - By Stock
|
MSB |
Re:
CEO Itescu needs to go
|
|
Cooper111
|
904 |
275K |
5 |
08/08/23 |
08/08/23 |
ASX - By Stock
|
904
|
275K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Update on BLA for Graft Versus Host Disease
|
|
Cooper111
|
1.0K |
389K |
5 |
05/08/23 |
05/08/23 |
ASX - By Stock
|
1.0K
|
389K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Update on BLA for Graft Versus Host Disease
|
|
Cooper111
|
1.0K |
389K |
7 |
05/08/23 |
05/08/23 |
ASX - By Stock
|
1.0K
|
389K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Update on BLA for Graft Versus Host Disease
|
|
Cooper111
|
1.0K |
389K |
5 |
05/08/23 |
05/08/23 |
ASX - By Stock
|
1.0K
|
389K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Update on BLA for Graft Versus Host Disease
|
|
Cooper111
|
1.0K |
389K |
9 |
05/08/23 |
05/08/23 |
ASX - By Stock
|
1.0K
|
389K
|
9
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Update on BLA for Graft Versus Host Disease
|
|
Cooper111
|
1.0K |
389K |
4 |
05/08/23 |
05/08/23 |
ASX - By Stock
|
1.0K
|
389K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Update on BLA for Graft Versus Host Disease
|
|
Cooper111
|
1.0K |
389K |
0 |
05/08/23 |
05/08/23 |
ASX - By Stock
|
1.0K
|
389K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Update on BLA for Graft Versus Host Disease
|
|
Cooper111
|
1.0K |
389K |
10 |
05/08/23 |
05/08/23 |
ASX - By Stock
|
1.0K
|
389K
|
10
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Update on BLA for Graft Versus Host Disease
|
|
Cooper111
|
1.0K |
389K |
1 |
04/08/23 |
04/08/23 |
ASX - By Stock
|
1.0K
|
389K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Update on BLA for Graft Versus Host Disease
|
|
Cooper111
|
1.0K |
389K |
14 |
04/08/23 |
04/08/23 |
ASX - By Stock
|
1.0K
|
389K
|
14
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Trading Halt
|
|
Cooper111
|
1.3K |
544K |
8 |
04/08/23 |
04/08/23 |
ASX - By Stock
|
1.3K
|
544K
|
8
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Trading Halt
|
|
Cooper111
|
1.3K |
544K |
14 |
02/08/23 |
02/08/23 |
ASX - By Stock
|
1.3K
|
544K
|
14
|
|
ASX - By Stock
|
MSB |
Re:
2023 The Final Countdown
|
|
Cooper111
|
3.4K |
1.1M |
9 |
27/04/23 |
27/04/23 |
ASX - By Stock
|
3.4K
|
1.1M
|
9
|
|
ASX - By Stock
|
MSB |
Re:
SRaGVHD - My Reimbursement and sales prediction
|
|
Cooper111
|
20 |
9.4K |
24 |
09/03/23 |
09/03/23 |
ASX - By Stock
|
20
|
9.4K
|
24
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Completes Resubmission of BLA to FDA for SR-aGVHD
|
|
Cooper111
|
914 |
286K |
4 |
17/02/23 |
17/02/23 |
ASX - By Stock
|
914
|
286K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Growing doubt on COVID-19 Application
|
|
Cooper111
|
4.7K |
1.0M |
6 |
15/11/22 |
15/11/22 |
ASX - By Stock
|
4.7K
|
1.0M
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Voluntary Suspension
|
|
Cooper111
|
332 |
117K |
30 |
08/08/22 |
08/08/22 |
ASX - By Stock
|
332
|
117K
|
30
|
|
ASX - By Stock
|
MSB |
Re:
MSB over $100.00 in 10 years
|
|
Cooper111
|
59 |
21K |
1 |
05/08/22 |
05/08/22 |
ASX - By Stock
|
59
|
21K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Rexlemestrocel-L to be Highlighted on Heart Failure Panel
|
|
Cooper111
|
109 |
38K |
17 |
12/07/22 |
12/07/22 |
ASX - By Stock
|
109
|
38K
|
17
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Remestemcel-L for COPD Published in Respiratory Research
|
|
Cooper111
|
91 |
30K |
26 |
25/05/21 |
25/05/21 |
ASX - By Stock
|
91
|
30K
|
26
|
|
ASX - By Stock
|
MSB |
Re:
Ann: COVID ARDS Trial Topline 60-Day Results
|
|
Cooper111
|
1.6K |
460K |
16 |
03/05/21 |
03/05/21 |
ASX - By Stock
|
1.6K
|
460K
|
16
|
|
ASX - By Stock
|
MSB |
Re:
Ann: COVID ARDS Trial Topline 60-Day Results
|
|
Cooper111
|
1.6K |
460K |
6 |
30/04/21 |
30/04/21 |
ASX - By Stock
|
1.6K
|
460K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Ann: COVID ARDS Trial Topline 60-Day Results
|
|
Cooper111
|
1.6K |
460K |
10 |
30/04/21 |
30/04/21 |
ASX - By Stock
|
1.6K
|
460K
|
10
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Phase 3 Chronic Low Back Pain Results
|
|
Cooper111
|
1.1K |
310K |
12 |
12/02/21 |
12/02/21 |
ASX - By Stock
|
1.1K
|
310K
|
12
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Cooper111
|
17K |
6.6M |
26 |
27/01/21 |
27/01/21 |
ASX - By Stock
|
17K
|
6.6M
|
26
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading 2021 - paradigm shift
|
|
Cooper111
|
10K |
3.0M |
24 |
15/01/21 |
15/01/21 |
ASX - By Stock
|
10K
|
3.0M
|
24
|
|
ASX - By Stock
|
MSB |
Re:
true facts
|
|
Cooper111
|
8 |
3.7K |
30 |
21/12/20 |
21/12/20 |
ASX - By Stock
|
8
|
3.7K
|
30
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Update on COVID-19 ARDS Trial
|
|
Cooper111
|
1.0K |
515K |
35 |
18/12/20 |
18/12/20 |
ASX - By Stock
|
1.0K
|
515K
|
35
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Update on COVID-19 ARDS Trial
|
|
Cooper111
|
1.0K |
515K |
31 |
18/12/20 |
18/12/20 |
ASX - By Stock
|
1.0K
|
515K
|
31
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Update on COVID-19 ARDS Trial
|
|
Cooper111
|
1.0K |
515K |
13 |
18/12/20 |
18/12/20 |
ASX - By Stock
|
1.0K
|
515K
|
13
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Update on COVID-19 ARDS Trial
|
|
Cooper111
|
1.0K |
515K |
24 |
18/12/20 |
18/12/20 |
ASX - By Stock
|
1.0K
|
515K
|
24
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
Cooper111
|
13K |
4.9M |
7 |
18/12/20 |
18/12/20 |
ASX - By Stock
|
13K
|
4.9M
|
7
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
Cooper111
|
13K |
4.9M |
7 |
17/12/20 |
17/12/20 |
ASX - By Stock
|
13K
|
4.9M
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Phase 3 DREAM HF-1 read-out
|
|
Cooper111
|
344 |
178K |
3 |
16/12/20 |
16/12/20 |
ASX - By Stock
|
344
|
178K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Remestemcel-L FDA Fast Track Designation for COVID-19 ARDS
|
|
Cooper111
|
572 |
250K |
24 |
04/12/20 |
04/12/20 |
ASX - By Stock
|
572
|
250K
|
24
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
Cooper111
|
13K |
4.9M |
30 |
03/12/20 |
03/12/20 |
ASX - By Stock
|
13K
|
4.9M
|
30
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Cooper111
|
17K |
6.6M |
35 |
27/11/20 |
27/11/20 |
ASX - By Stock
|
17K
|
6.6M
|
35
|
|
ASX - By Stock
|
MSB |
Re:
Ann: DSMB Analysis Recommends to Continue P3 COVID-19 ARDS Trial
|
|
Cooper111
|
392 |
157K |
7 |
11/11/20 |
11/11/20 |
ASX - By Stock
|
392
|
157K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Overwhelming efficacy - the stats required
|
|
Cooper111
|
576 |
230K |
5 |
26/10/20 |
26/10/20 |
ASX - By Stock
|
576
|
230K
|
5
|
|